Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer

Journal of Urology

Volumn 171, Issue 6 I, 2004, Pages 2272-2276

  Sieber, Paul R ^a   Keiller, Danny L ^b   Kahnoski, Richard J ^b   Gallo, Jose ^b   McFadden, Scott ^b  

^a Urological Associates of Lancaster   (United States)

^b NONE

Author keywords

Androgen antagonists; Body composition; Bone density; Castration; Prostatic neoplasms

Indexed keywords

ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; GONADORELIN DERIVATIVE; LIPID;

ADULT; ADVANCED CANCER; AGED; ARTHRITIS; ARTICLE; ASTHENIA; BACKACHE; BODY COMPOSITION; BONE DENSITY; BONE MINERAL; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CASTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; GOOD CLINICAL PRACTICE; GYNECOMASTIA; HIP; HOT FLUSH; HUMAN; HYPERTENSION; HYPOGONADISM; INSOMNIA; LIPID BLOOD LEVEL; LIVER DYSFUNCTION; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MONOTHERAPY; MULTICENTER STUDY; MUSCLE ATROPHY; MUSCLE MASS; OPEN STUDY; OSTEOLYSIS; PAIN; PELVIS PAIN SYNDROME; PHARYNGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RASH; SINUSITIS; VERTIGO;

EID: 2442581156     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000127738.94221.da     Document Type: Article

References (20)

1. Berruti, A., Dogliotti, L., Terrone, C., Cerutti, S., Isaia, G., Tarabuzzi, R. et al: Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol, 167: 2361, 2002
2. Daniell, H. W., Dunn, S. R., Ferguson, D. W., Lomas, G., Niazi, Z. and Stratte, P. T.: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol, 163: 181, 2000
3. Maillefert, J. F., Sibilia, J., Michel, F., Saussine, C., Javier, R. M. and Tavernier, C.: Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol, 161: 1219, 1999
4. Hatano, T., Oishi, Y., Furuta, A., Iwamuro, S. and Tashiro, K.: Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int, 86: 449, 2000
5. Daniell, H. W.: Osteoporosis after orchiectomy for prostate cancer. J Urol, 157: 439, 1997
6. Basaria, S., Lieb, J., 2nd, Tang, A. M., DeWeese, T., Carducci, M., Eisenberger, M. et al: Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol, 56: 779, 2002
7. Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A. et al: Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab, 87: 599, 2002
8. Smith, J. C., Bennett, S., Evans, L. M., Kynaston, H. G., Parmar, M., Mason, M. D. et al: The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab, 86: 4261, 2001
9. Stoch, S. A., Parker, R. A., Chen, L., Bubley, G., Ko, Y. J., Vincelette, A. et al: Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab, 86: 2787, 2001
10. Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N. et al: Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab, 281: E1172, 2001
11. Iversen, P., Tyrrell, C. J., Kaisary, A. V., Anderson, J. B., Van Poppel, H., Tammela, T. L. J. et al: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol, 164: 1579, 2000
12. See, W. A., Wirth, M. P., McLeod, D. G., Iversen, P., Klimberg, I., Gleason, D. et al: Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol, 168: 429, 2002
13. Verhelst, J., Denis, L., Van Vliet, P., Van Poppel, H., Braeckman, J., Van Cangh, P. et al: Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf), 41: 525, 1994
14. Tyrrell, C. J., Blake, G. M., Iversen, P., Kaisary, A. V. and Melezinek, I.: The non-steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World J Urol, 21: 37, 2003
15. Smith, M. R., Fallon, M. A. and Goode, M. J.: Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology, 61: 127, 2003
16. Broulik, P. D. and Starka, L.: Effect of antiandrogens casodex and epitestosterone on bone composition in mice. Bone, 20: 473, 1997
17. Calero, J. A., Diaz-Curiel, M. and de al Piedra, C.: Bicalutamide (Casodex) treatment does not produce bone effects in male Wistar rats. J Bone Min Res, suppl., 14: S220, abstract F034, 1999
18. Suzuki, Y., Aikawa, K., Oishi, Y., Yamazaki, H., Onishi, T., Suzuki, M. et al: A clinical study of decreased bone density in the patients treated with long-term luteinizing hormone releasing hormone analogue (LHRH-a) - the risk of iatrogenic osteoporosis due to treatment of carcinoma of prostate. Nippon Hinyokika Gakkai Zasshi, 89: 961, 1998
19. Grinspoon, S., Corcoran, C., Lee, K., Burrows, B., Hubbard, J., Katznelson, L. et al: Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab, 81: 4051, 1996
20. Herr, H. W. and O'Sullivan, M.: Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol, 163: 1743, 2000